ARGX · available-data snapshot
argenx SE (ARGX): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for argenx SE (ARGX); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for ARGX?
We do not publish a fair value for argenx SE. What we can say from its filings and market data is below.
What is ARGX's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: looks expensive on the numbers.
- Value · 20 of 100
Cheaper than 20% of Healthcare companies in US
- Price vs worth · 24 of 100
- Quality · 79 of 100
More profitable than 79% of Healthcare companies in US
- Financial health · 82 of 100
Financially stronger than 82% of Healthcare companies in US
- Growth · 70 of 100
Growing faster than 70% of Healthcare companies in US
- Momentum · 38 of 100
Outperformed 38% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $819.96
- Market cap
- $51,
564, 220, 416 - 52-week high
- $1,
073 - 52-week low
- $661.85
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for argenx SE (ARGX) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, ARGX trades at a recent price of $819.96, a market capitalisation of about $51,564,220,416, sitting 38% of the way up its 52-week range ($661.85–$1,073), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing ARGX's trading multiples against a sector benchmark. Here that gives P/E of 31.2× (cheaper than the peer median of 41.9×); Fwd P/E of 23.0× (richer than the peer median of 17.5×); P/B of 152.3× (richer than the peer median of 7.8×); P/S of 9.7× (richer than the peer median of 6.2×); EV/EBITDA of 790.8× (richer than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. ARGX shows a price-to-book (P/B) of 152.31 and book value of $5.38 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. ARGX is in a mixed trend, trading -23.6% from its 52-week high. Over the past year the stock is -3.6%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
ARGX vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | ARGX | Peer median | Read |
|---|---|---|---|
| P/E | 31.2× | 41.9× | cheaper than |
| Fwd P/E | 23.0× | 17.5× | richer than |
| P/B | 152.3× | 7.8× | richer than |
| P/S | 9.7× | 6.2× | richer than |
| EV/EBITDA | 790.8× | 18.5× | richer than |
What does argenx SE do?
What does it do?
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It operates in the Biotechnology industry (Healthcare sector), headquartered in Netherlands. The company employs roughly 1,863 people.
How does it make money?
The business turns $4.2B in annual revenue into profit. Out of every $100 of sales, about $32 is left as operating profit (operating margin of 32.0%), after a 59% gross margin on the products/services it sells. After all costs, taxes and interest, 32.3% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.6× equity), comfortably covers its short-term bills (5.1× current ratio), and is currently profitable.
ARGX insider trading
We have no recent SEC Form 4 insider filings on file for argenx SE. Form 4 covers US-listed companies only.
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.